Features of glucose metabolism in acromegaly depending on the type of treatment

Aim of the study was to investigate the features of glucose metabolism in patients with acromegaly depending on treatment. Materials and methods: 63 patients with acromegaly: 29 patients with newly diagnosed acromegaly, 25 patients receiving somatostatin analogs (SSA) therapy and 9 patients underwent surgical treatment. Patients with earlier revealed diabetes mellitus (DM) were not included. The characterization of glucose metabolism was carried out by means of an assessment of fasting insulin plasma levels (FIP) and indexes of an insulinresistance (IR) HOMA-R and an insulinsensivity (IS) MATSUDA. Results: In patients receiving SSA therapy the carbohydrate metabolism disorders (CMD) were revealed in 92%, among newly diagnosed acromegalic patients – in 62% and in patients after surgical treatment in 33% of cases. In newly diagnosed acromegalic patients index MATSUDA was 3,5 times lower than in patients receiving SSA therapy, and 4 times lower than in patients after surgical treatment ((р=0,001). НОМА-R in newly diagnosed acromegalic patients was 3,7 times higher than in other groups, p=0,003 and the level of FIP was 4,3 times higher than in patients receiving SSA therapy and 2,9 times higher than in patients after surgical treatment (р=0,001). The index MATSUDA in newly diagnosed acromegalic patients with early CMD was 2,9 times lower, р=0,006, НОМА-R – 2,5 times higher, р=0,025 and FIP 2,4 times higher, р=0,039 than in patients with early CMDs without acromegaly. Conclusions: In patients with newly diagnosed acromegaly in the absence of CMDs increase in IR is compensated by hyperinsulinemia. In patients, receiving SSA therapy the IR decreases, however suppression of secretion of insulin leads to increase in percentage of DM in this group. After surgical treatment IR decreases against higher level of fasting plasma insulin that leads to normalization of carbohydrate metabolism. Keywords: Acromegaly, secondary diabetes mellitus, insulinresistance, MATSUDA, HOMA-R.

Acromegaly, secondary diabetes mellitus, insulinresistance, MATSUDA, HOMA-R, MATSUDA, HOMA-R

1. Древаль А.В., Триголосова И.В., Виноградова А.В., Иловайская И.А. Распространенность сахарного диабета среди больных акромегалией. Проблемы эндокринологии. 2012; 3: 9–11.

2. Древаль А.В., Триголосова И.В., Виноградова А.В., Тишенина Р.С., Мисникова И.В., Губкина В.А., Ковалева Ю.А., Барсуков И.А. Распространенность ранних нарушений углеводного обмена среди больных акромегалией. Проблемы эндокринологии. 2012; 6: 3–7.

3. Cherrington A.D., Stevenson R.W., Steiner K.E., et al. Insulin, glucagon and glucose as regulators of hepatic glucose uptake and production in vivo. Diabetes Metab. Rev. 1987; 3: 307–332.

4. Colao A., Auriemma R.S., Galdiero M., Lombardi G., Pivonello R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab.2009; 94: 3746–3756.

5. Colao A., Ferone D., Marzullo P., Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004; 25: 102–152.

6. Colao A., Pivonello R., Galderisi M., Cappabianca P., Auriemma R.S., Galdiero M., Cavallo L.M., Esposito F., Lombardi G. // Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab. 2008; 93: 2639–2646.

7. DeFronzo R.A., Ferrannini E., Simonson D.C. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 1989; 38: 387 –395.

8. Definition, diagnosis and classification of Diabetes Mellitus and its complications. Geneva, W.H.O, 1999.

9. Dreval A., Trigolosova I., Vinogradova A., Ilovayskaya I. Prevalence of diabetes mellitus among acromegaly patients. Abstracts of the 15th Congress of the European Neuroendocrine Association, Wien, 22–25 September 2012; P 40.

10. Fieffe S., Morange I., Petrossians P., Chanson P., Rohmer V., Cortet C., Borson-Chazot F., Brue T., Delemer B. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol. 2011 Jun; 164 (6): 877–84; Epub 2011 Apr 4.

11. Holdaway I.M., Rajasoorya C. Epidemiology of acromegaly. Pituitary. 1999 Jun; 2 (1): 29–41.

12. IDF Diabetes Atlas, Fifth Edition, International Diabetes Federation. 2011; 7.

13. Kreze A., Kreze-Spirova E., Mikulecky M. Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res. 2001; 34: 1429–1433.

14. Matsuda M., DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the uglycemic glucose clamp. Diabetes Care. 1999; 22: Р. 1462–1470.

15. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985; Vol. 28; 412–419.

16. Melmed S., Colao A., Barkan A., Molitch M., Giustina A. et al. Guidelines for Acromegaly Management: An Update. J Clin Endocrinol Metab. 2009; 94 (5): 1509–1517.

17. Nabarro J.D.N. Acromegaly. Clin Endocrinol (Oxf). 1987; 26: 481–512.

18. Resmini E., Minuto F., Colao A., Ferone D. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol. 2009; 46; № 2: 85–95.

19. Ronchi C.L., Varca V., Beck-Peccoz P., Orsi E., Donadio F., Baccarelli A., Giavoli C., Ferrante E., Lania A., Spada A., Arosio M. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab. 2006; 91: 121–128.